VNDA241220P9000
- 4.00
- 0.000.00%
Vanda Pharmaceuticals Newsroom
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $18
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $13
Vanda Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Vanda Pharmaceuticals Inc : Jefferies Cuts Target Price to $5.5 From $6
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript Summary
Vanda Pharmaceuticals | 8-K: Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
Vanda Pharmaceuticals GAAP EPS of -$0.09 Beats by $0.07, Revenue of $47.7M Misses by $1.45M
Express News | Vanda Pharmaceuticals Inc FY2024 Rev View $198.3 Mln -- LSEG IBES Data
Express News | Vanda Pharmaceuticals Inc -Financial Guidance Revised for Full Year 2024, Raising the Midpoint of Revenue and Cash Ranges
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M
Express News | Vanda Pharmaceuticals Q3 Net Income USD -5.324 Million
Express News | Vanda Pharmaceuticals Q3 Basic EPS USD -0.09
Express News | Vanda Pharmaceuticals Q3 Operating Income USD -11 Million
Express News | Vanda Pharmaceuticals Q3 Operating Expenses USD 58.651 Million
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
Earnings Preview: VNDA to Report Financial Results Post-market on November 06
Vanda Started at Buy by H.C. Wainwright, Negative Enterprise Value Cited